Pharmaceuticals in Canadian sewage treatment plant effluents and surface waters: occurrence and environmental risk assessment

Environmental Technology Reviews

Volumn 2, Issue 1, 2013, Pages 17-27

  Koné, Macoura ^a   Cologgi, Dena L ^a   Lu, Weibing ^a   Smith, Daniel W ^a   Ulrich, Ania C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Canadian aquatic environments; environmental risk assessment; pharmaceuticals; sewage treatment plant effluents; surface water

Indexed keywords

EID: 85051853180     PISSN: 21622515     EISSN: 21622523     Source Type: Journal    
DOI: 10.1080/21622515.2013.865793     Document Type: Review

References (75)

1. Daughton CG, Ternes TA. Pharmaceuticals and personal care products in the environment: agents of subtle change? Environ Health Perspect. 1999;107(Suppl 6):907–938. doi: 10.1289/ehp.99107s6907
2. Robinson I, Junqua G, Van Coillie R, Thomas O. Trends in the detection of pharmaceutical products, and their impact and mitigation in water and wastewater in North America. Anal Bioanal Chem. 2007;387:1143–1151. doi: 10.1007/s00216-006-0951-y
3. Hua WY, Bennett ER, Maio XS, Metcalfe CD, Letcher RJ. Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River. Environ Toxicol Chem. 2006;25:2356–2365. doi: 10.1897/05-571R.1
4. Metcalfe CD, Koenig BG, Bennie DT, Servos M, Ternes TA, Hirsch R. Occurrence of neutral and acidic drugs in the effluents of Canadian sewage treatment plants. Environ Toxicol Chem. 2003;22:2872–2880. doi: 10.1897/02-469
5. Metcalfe CD, Miao XS, Koenig BG, Struger J. Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada. Environ Toxicol Chem. 2003;22:2881–2889. doi: 10.1897/02-627
6. Servos MR, Smith M, McInnis R, Burnison BK, Lee B, Seto P, Backus S. The presence of selected pharmaceuticals and the antimicrobial triclosan in drinking water in Ontario, Canada. Water Qual Res J Can 2007;42:130–137.
7. Brun GL, Bernier M, Losier R, Doe K, Jackman P, Lee HB. Pharmaceutically active compounds in Atlantic Canadian sewage treatment plant effluents and receiving waters, and potential for environmental effects as measured by acute and chronic aquatic toxicity. Environ Toxicol Chem. 2006;25:2163–2176. doi: 10.1897/05-426R.1
8. Carballa M, Omil F, Lema JM, Llompart M, Garcia-Jares C, Rodriguez I, Gomez M, Ternes T. Behavior of pharmaceuticals, cosmetics and hormones in a sewage treatment plant. Water Res. 2004;38:2918–2926. doi: 10.1016/j.watres.2004.03.029
9. Chen M, Ohman K, Metcalfe C, Ikonomou MG, Amatya PL, Wilson J. Pharmaceuticals and endocrine disruptors in wastewater treatment effluents and in the water supply system of Calgary, Alberta, Canada. Water Qual Res J Can. 2006;41:351–364.
10. Gagne F, Blaise C, Andre C. Occurrence of pharmaceutical products in a municipal effluent and toxicity to rainbow trout (Oncorhynchus mykiss) hepatocytes. Ecotoxicol Environ Saf. 2006;64:329–336. doi: 10.1016/j.ecoenv.2005.04.004
11. Heberer T, Reddersen K. Occurrence and fate of pharmaceuticals residues in the aquatic system of Berlin as an example for urban ecosystems. Second International Conference on Pharmaceuticals and Endocrine Disrupting Chemicals in Water; October 9–11. Minneapolis (MN): National Ground Water Association; 2001.
12. Heberer T. Tracking persistent pharmaceuticals residues from municipal sewage to drinking water. J Hydrol. 2002;266:175–189. doi: 10.1016/S0022-1694(02)00165-8
13. Servos MR, Bennie DT, Starodub ME, Orr JC. Pharmaceuticals and personal care products in the environment: a summary of published literature. Burlington/Saskatoon: Environment Canada, National Water Research Institute; 2002.
14. Ternes TA. Occurrence of drugs in German sewage treatment plants and rivers. Water Res. 1998;32:3245–3260. doi: 10.1016/S0043-1354(98)00099-2
15. Crane M, Watts C, Boucard T. Chronic aquatic environmental risks from exposure to human pharmaceuticals. Sci Total Environ. 2006;367:23–41. doi: 10.1016/j.scitotenv.2006.04.010
16. Flaherty CM, Dodson SI. Effects of pharmaceuticals on Daphnia survival, growth, and reproduction. Chemosphere. 2005;61:200–207. doi: 10.1016/j.chemosphere.2005.02.016
17. Parrott JL. Pharmaceuticals and personal care products in the Canadian environment. Environment Canada Workshop on the Effects of Pharmaceuticals and Personal Care Products in the Environment, PowerPoint Presentation; 2006.
18. Parrott JL, Blunt BR. Life-cycle exposure of fathead minnows (Pimephales promelas) to an ethinylestradiol concentration below 1 ng/L reduces egg fertilization success and demasculinizes males. Environ Toxicol. 2005;20:131–141. doi: 10.1002/tox.20087
19. Pomati F, Orlandi C, Clerici M, Luciani F, Zuccato E. Effects and interactions in an environmentally relevant mixture of pharmaceuticals. Toxicol Sci. 2008;102:129–137. doi: 10.1093/toxsci/kfm291
20. Santos LH, Araujo AN, Fachini A, Pena A, Delerue-Matos C, Montenegro MC. Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. J Hazard Mater. 2010;175:45–95. doi: 10.1016/j.jhazmat.2009.10.100
21. Stackelberg PE, Furlong ET, Meyer MT, Zaugg SD, Henderson AK, Reissman DB. Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-water-treatment plant. Sci Total Environ. 2004;329:99–113. doi: 10.1016/j.scitotenv.2004.03.015
22. Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, Buxton HT. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000: a national reconnaissance. Environ Sci Technol. 2002;36:1202–1211. doi: 10.1021/es011055j
23. Metcalfe CD, Miao XS, Hua W, Letcher R, Servos MR. Pharmaceuticals in the Canadian environment. In: Kümmerer K, editor. Pharmaceuticals in the environment: sources, fate, effects, and risks. Berlin: Springer; 2004. p. 67–90.
24. Kleywegt S, Smyth S, Parrott J, Schaefer K, Lagacé E, Payne M, Topp E, Beck A, McLaughlin A, Ostapyk K. Pharmaceuticals and personal care products in the Canadian environment: research and policy directions. In: NWRI Scientific Assessment Report Series No. 8; 2007. p. 53.
25. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Social Res Method. 2005;8:19–32. doi: 10.1080/1364557032000119616
26. Pawson R. Evidence-based policy: in search of a method. Evaluation. 2002;8:157–181.
27. Bound JP, Voulvoulis N. Pharmaceuticals in the aquatic environment–a comparison of risk assessment strategies. Chemosphere. 2004;56:1143–1155. doi: 10.1016/j.chemosphere.2004.05.010
28. EMEA. Note for guidance on environmental risk assessment of medicinal products for human use, CPNP/SWP/4447/00 draft corr. London: European Agency for the Evaluation of Medicinal Products; 2005.
29. Santos JL, Aparicio I, Alonso E. Occurrence and risk assessment of pharmaceutically active compounds in wastewater treatment plants. A case study: Seville City (Spain). Environ Int. 2007;33:596–601.
30. E.A.f.t.E.o.M.P. (EAEMP). Draft CPMP discussion paper on environmental risk assessment of non-genetically modified organisms (non-GMO) containing medicinal products for human use, CPMP/SWP/4447/00. London: European Agency for the Evaluation of Medical Products (EAEMP); 2001.
31. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep. 2004;6:148–157. doi: 10.1007/s11883-004-0104-8
32. Laville N, Ait-Aissa S, Gomez E, Casellas C, Porcher JM. Effects of human pharmaceuticals on cytotoxicity, EROD activity and ROS production in fish hepatocytes. Toxicology. 2004;196:41–55. doi: 10.1016/j.tox.2003.11.002
33. Batt AL, Kim S, Aga DS. Comparison of the occurrence of antibiotics in four full-scale wastewater treatment plants with varying designs and operations. Chemosphere. 2007;68:428–435. doi: 10.1016/j.chemosphere.2007.01.008
34. Ferrari B, Paxeus N, Lo Giudice R, Pollio A, Garric J. Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac. Ecotoxicol Environ Saf. 2003;55:359–370. doi: 10.1016/S0147-6513(02)00082-9
35. Brain RA, Johnson DJ, Richards SM, Sanderson H, Sibley PK, Solomon KR. Effects of 25 pharmaceutical compounds to Lemna gibba using a seven-day static-renewal test. Environ Toxicol Chem. 2004;23:371–382. doi: 10.1897/02-576
36. Brooks BW, Foran CM, Richards SM, Weston J, Turner PK, Stanley JK, Solomon KR, Slattery M, La Point TW. Aquatic ecotoxicology of fluoxetine. Toxicol Lett. 2003;142: 169–183. doi: 10.1016/S0378-4274(03)00066-3
37. Brooks BW, Turner PK, Stanley JK, Weston JJ, Glidewell EA, Foran CM, Slattery M, La Point TW, Huggett DB. Waterborne and sediment toxicity of fluoxetine to select organisms. Chemosphere. 2003;52:135–142. doi: 10.1016/S0045-6535(03)00103-6
38. Cleuvers M. Aquatic ecotoxicity of pharmaceuticals including the assessment of combination effects. Toxicol Lett. 2003;142:185–194. doi: 10.1016/S0378-4274(03)00068-7
39. Eguchi K, Nagase H, Ozawa M, Endoh YS, Goto K, Hirata K, Miyamoto K, Yoshimura H. Evaluation of antimicrobial agents for veterinary use in the ecotoxicity test using microalgae. Chemosphere. 2004;57:1733–1738. doi: 10.1016/j.chemosphere.2004.07.017
40. Farre ML, Ferrer I, Ginebreda A, Figueras M, Olivella L, Tirapu L, Vilanova M, Barcelo D. Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry: methods and preliminary results including toxicity studies with Vibrio fischeri. J Chromatogr A. 2001;938:187–197. doi: 10.1016/S0021-9673(01)01154-2
41. Ferrari B, Mons R, Vollat B, Fraysse B, Paxeus N, Lo Giudice R, Pollio A, Garric J. Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment? Environ Toxicol Chem. 2004;23:1344–1354. doi: 10.1897/03-246
42. Halling-Sorensen B, Lutzhoft HC, Andersen HR, Ingerslev F. Environmental risk assessment of antibiotics: comparison of mecillinam, trimethoprim and ciprofloxacin. J Antimicrob Chemother. 2000;46(Suppl 1):53–58; discussion 63–65. doi: 10.1093/jac/46.suppl_1.53
43. Halling-Sorensen B, Nors Nielsen S, Lanzky PF, Ingerslev F, Holten Lutzhoft HC, Jorgensen SE. Occurrence, fate and effects of pharmaceutical substances in the environment–a review. Chemosphere. 1998;36:357–393. doi: 10.1016/S0045-6535(97)00354-8
44. Henschel KP, Wenzel A, Diedrich M, Fliedner A. Environmental hazard assessment of pharmaceuticals. Regul Toxicol Pharmacol. 1997;25:220–225. doi: 10.1006/rtph.1997.1102
45. Huggett DB, Brooks BW, Peterson B, Foran CM, Schlenk D. Toxicity of select beta adrenergic receptor-blocking pharmaceuticals (β-blockers) on aquatic organisms. Arch Environ Contam Toxicol. 2002;43:229–235. doi: 10.1007/s00244-002-1182-7
46. Jos A, Repetto G, Rios JC, Hazen MJ, Molero ML, del Peso A, Salguero M, Fernandez-Freire P, Perez-Martin JM, Camean A. Ecotoxicological evaluation of carbamazepine using six different model systems with eighteen endpoints. Toxicol In Vitro. 2003;17:525–532. doi: 10.1016/S0887-2333(03)00119-X
47. Knoll Pharmaceuticals. BASF Pharma safety data sheet: ibuprofen. Nottingham, England: Knolls Pharmaceuticals; 1995.
48. Marking LL, Howe GE, Crowther JR. Toxicity of erythromycin, oxytetracycline and tetracycline administered to lake trout in water baths by injection or by feeding. Prog Fish Cult. 1988;50:197–201. doi: 10.1577/1548-8640(1988)050<0197:TOEOAT>2.3.CO;2
49. Yu J, Bouwer E, Coelhan M. Occurrence and biodegradability studies of selected pharmaceuticals and personal care products in sewage effluent. Agric Water Manage. 2006;86:72–80. doi: 10.1016/j.agwat.2006.06.015
50. Comeau F, Surette C, Brun GL, Losier R. The occurrence of acidic drugs and caffeine in sewage effluents and receiving waters from three coastal watersheds in Atlantic Canada. Sci Total Environ. 2008;396:132–146. doi: 10.1016/j.scitotenv.2008.02.031
51. Gomez MJ, Martinez Bueno MJ, Lacorte S, Fernandez-Alba AR, Aguera A. Pilot survey monitoring pharmaceuticals and related compounds in a sewage treatment plant located on the Mediterranean coast. Chemosphere. 2007;66: 993–1002. doi: 10.1016/j.chemosphere.2006.07.051
52. Lee HB, Peart TE, Svoboda ML. Determination of endocrine-disrupting phenols, acidic pharmaceuticals, and personal-care products in sewage by solid-phase extraction and gas chromatography-mass spectrometry. J Chromatogr A. 2005;1094:122–129. doi: 10.1016/j.chroma.2005.07.070
53. Miao XS, Yang JJ, Metcalfe CD. Carbamazepine and its metabolites in wastewater and in biosolids in a municipal wastewater treatment plant. Environ Sci Technol. 2005;39:7469–7475. doi: 10.1021/es050261e
54. Health Canada. Drug product database. Ottawa, Ontario: Health Canada; 2006.
55. Sosiak AJ, Hebben T. A preliminary survey of pharmaceuticals and endocrine disrupting compounds in treated municipal wastewaters and receiving rivers of Alberta. Edmonton, Alberta, Canada: Alberta Environment, Environmental Monitoring and Evaluation Branch; 2005.
56. Watkinson AJ, Murby EJ, Kolpin DW, Costanzo SD. The occurrence of antibiotics in an urban watershed: from wastewater to drinking water. Sci Total Environ. 2009;407:2711–2723. doi: 10.1016/j.scitotenv.2008.11.059
57. Hao C, Lissemore L, Nguyen B, Kleywegt S, Yang P, Solomon K. Determination of pharmaceuticals in environmental waters by liquid chromatography/electrospray ionization/tandem mass spectrometry. Anal Bioanal Chem. 2006;384:505–513. doi: 10.1007/s00216-005-0199-y
58. Lissemore L, Hao C, Yang P, Sibley PK, Mabury S, Solomon KR. An exposure assessment for selected pharmaceuticals within a watershed in Southern Ontario. Chemosphere. 2006;64:717–729. doi: 10.1016/j.chemosphere.2005.11.015
59. Ontario Ministry of the Environment. Survey of the occurrence of pharmaceuticals and other emerging contaminants in untreated source and finished drinking water in Ontario. Toronto, Ontario: Ontario Ministry of the Environment; 2010.
60. Kuchta SL, Cessna AJ. Fate of lincomycin in snowmelt runoff from manure-amended pasture. Chemosphere. 2009; 76:439–446. doi: 10.1016/j.chemosphere.2009.03.069
61. Hemels ME, Koren G, Einarson TR. Increased use of antidepressants in Canada: 1981–2000. Ann Pharmacother. 2002; 36:1375–1379.
62. DeVane CL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol. 1999;19:443–466. doi: 10.1023/A:1006934807375
63. Metcalfe CD, Chu S, Judt C, Li H, Oakes KD, Servos MR, Andrews DM. Antidepressants and their metabolites in municipal wastewater, and downstream exposure in an urban watershed. Environ Toxicol Chem. 2010;29:79–89. doi: 10.1002/etc.27
64. Lajeunesse A, Gagnon C, Sauve S. Determination of basic antidepressants and their N-desmethyl metabolites in raw sewage and wastewater using solid-phase extraction and liquid chromatography-tandem mass spectrometry. Anal Chem. 2008;80:5325–5333. doi: 10.1021/ac800162q
65. Albani F, Riva R, Baruzzi A. Carbamazepine clinical pharmacology: a review. Pharmacopsychology 1995;28: 235–244. doi: 10.1055/s-2007-979609
66. Israel M, Beaudry P. Carbamazepine in psychiatry: a review. Can J Psychiatry. 1988;33:577–584.
67. Lertratanangkoon K, Horning MG. Metabolism of carbamazepine. Drug Metab Dispos. 1982;10:1–10.
68. Miao XS, Metcalfe CD. Determination of carbamazepine and its metabolites in aqueous samples using liquid chromatography-electrospray tandem mass spectrometry. Anal Chem. 2003;75:3731–3738. doi: 10.1021/ac030082k
69. Andreozzi R, Marotta R, Pinto G, Pollio A. Carbamazepine in water: persistence in the environment, ozonation treatment and preliminary assessment on algal toxicity. Water Res. 2002;36:2869–2877. doi: 10.1016/S0043-1354(01)00500-0
70. Lee HB, Sarafin K, Peart TE. Determination of β-blockers and β2-agonists in sewage by solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2007;1148:158–167. doi: 10.1016/j.chroma.2007.03.024
71. Nikolai LN, McClure EL, Macleod SL, Wong CS. Stereoisomer quantification of the β-blocker drugs atenolol, metoprolol, and propranolol in wastewaters by chiral high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2006;1131:103–109. doi: 10.1016/j.chroma.2006.07.033
72. Scheurer M, Ramil M, Metcalfe CD, Groh S, Ternes TA. The challenge of analyzing β-blocker drugs in sludge and wastewater. Anal Bioanal Chem. 2010;396:845–856. doi: 10.1007/s00216-009-3225-7
73. Winkler M, Lawrence JR, Neu TR. Selective degradation of ibuprofen and clofibric acid in two model river biofilm systems. Water Res. 2001;35:3197–3205. doi: 10.1016/S0043-1354(01)00026-4
74. Lee HB, Peart TE, Svoboda ML, Backus S. Occurrence and fate of rosuvastatin, rosuvastatin lactone, and atorvastatin in Canadian sewage and surface water samples. Chemosphere. 2009;77:1285–1291. doi: 10.1016/j.chemosphere.2009.09.068
75. Thomas DJ, Tyrrel SF, Smith R, Farrow S. Bioassays for the evaluation of landfill leachate toxicity. J Toxicol Environ Health B Crit Rev. 2009;12:83–105. doi: 10.1080/10937400802545292